The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions.
Apocrine Glands
/ pathology
Biomarkers, Tumor
/ metabolism
Breast
/ metabolism
Breast Neoplasms
/ diagnosis
Enhancer of Zeste Homolog 2 Protein
/ metabolism
Epithelial Cells
/ pathology
Female
Humans
Hyperplasia
/ pathology
Ki-67 Antigen
/ metabolism
Metaplasia
/ pathology
Precancerous Conditions
/ pathology
Apocrine
Atypia
Atypical apocrine adenosis
DCIS
DIN
EZH2
Ki-67
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
24
03
2020
revised:
14
05
2020
accepted:
31
05
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
2
7
2021
Statut:
ppublish
Résumé
In diagnostic breast pathology, there is no reliable applicable immunostain to help discern atypical and in situ apocrine lesions from benign apocrine tissue. At present, the diagnosis of non-invasive apocrine lesions remains challenging with current diagnoses rendered based on discrete morphologic characteristics on conventional hematoxylin and eosin staining. Interobserver variability is significant even among subspecialists partly due to lack of adjuvant diagnostic immunohistochemical stains. Herein, we set to elucidate the potential utility of EZH2 and Ki-67 immunostains as tangible tools in non-invasive apocrine proliferations. A cohort of apocrine breast lesions [Benign apocrine hyperplasia (BAH), n = 10; Atypical apocrine hyperplasia (AAH), n = 16; Apocrine ductal carcinoma in situ (ADCIS), n = 12] were subjected to EZH2 immunostaining and analyzed via H-scoring of nuclear expression. Mean H-scores for EZH2 progressively increased from BAH (23.5), to AAH (47.4) and ADCIS (196.4), and showed a significant difference utilizing the Kruskal-Wallis test (p < 0.0001). Further interrogation of Ki-67 demonstrated incremental expression from BAH to AAH and ADCIS at 1.6 %, 4.7 % and 24.7 %, respectively (p < 0.0001, Kruskal-Wallis test), suggesting an association with increased proliferation. Our results demonstrate that a combination of EZH2 and Ki-67 immunostaining may be employed in differentiating among challenging apocrine breast lesions and suggest a putative diagnostic utility for EZH2 and Ki-67 in non-invasive apocrine breast lesions.
Identifiants
pubmed: 32825929
pii: S0344-0338(20)30876-1
doi: 10.1016/j.prp.2020.153041
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153041Informations de copyright
Copyright © 2020 Elsevier GmbH. All rights reserved.